Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Takeda Pharmaceutical Company Limited, commonly known as Takeda, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Japan (JP). Founded in 1781, Takeda has a rich history marked by significant milestones, including its expansion into global markets and a commitment to innovative healthcare solutions.
With a strong presence in regions such as North America, Europe, and Asia, Takeda focuses on key therapeutic areas including oncology, gastroenterology, and neuroscience. The company is renowned for its core products, which are distinguished by their scientific rigor and patient-centric approach.
As a top-tier pharmaceutical manufacturer, Takeda has achieved notable recognition for its contributions to healthcare, consistently ranking among the largest pharmaceutical companies worldwide. Its dedication to research and development positions Takeda as a pioneer in delivering transformative therapies that address unmet medical needs.
+34 vs industry average
Takeda’s score of 76 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Takeda, a pharmaceutical preparation manufacturing company headquartered in Japan, has established comprehensive climate commitments with evolving emissions reporting.
In 2025, Takeda reported Scope 1 emissions of approximately 246,000,000 kg CO2e and Scope 2 (market-based) emissions of approximately 28,000,000 kg CO2e. For 2024, Scope 1 emissions were approximately 273,000,000 kg CO2e, with Scope 2 (market-based) at approximately 28,000,000 kg CO2e. In 2023, Scope 1 emissions were approximately 279,000,000 kg CO2e, and Scope 2 (market-based) were approximately 33,000,000 kg CO2e.
Looking further back, Takeda reported total emissions of approximately 5,612,000,000 kg CO2e for 2022, which included Scope 1 emissions of approximately 277,000,000 kg CO2e, Scope 2 (market-based) emissions of approximately 169,000,000 kg CO2e, and Scope 3 emissions of approximately 2,995,000,000 kg CO2e. For 2021, total emissions were approximately 5,210,000,000 kg CO2e, with Scope 1 emissions at approximately 316,000,000 kg CO2e, Scope 2 (market-based) at approximately 178,000,000 kg CO2e, and Scope 3 at approximately 4,716,000,000 kg CO2e. In 2020, total emissions were approximately 4,909,000,000 kg CO2e, with Scope 1 at approximately 293,000,000 kg CO2e, Scope 2 (market-based) at approximately 217,000,000 kg CO2e, and Scope 3 at approximately 4,380,000,000 kg CO2e.
Takeda has set ambitious reduction targets aligned with climate science. The company is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2040. More specifically, Takeda aims to reduce absolute Scope 1 and 2 GHG emissions by 65% by FY2030 from a FY2016 base year, and by 90% by FY2035 from the same base year. Furthermore, Takeda commits to reducing absolute Scope 3 GHG emissions by 25% by FY2030 from a FY2022 base year, and by 90% by FY2040 from a FY2022 base year. Takeda also aims to achieve net-zero emissions across its operations by 2030. The company is also committed to having 67% of its suppliers, by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, achieve science-based targets by 2024.
Access structured emission data, company specific factors and auditable source documents
2035
90% reduction in Scope 2
Takeda Pharmaceutical Company commits to reduce absolute scope 2 GHG emissions 90% by FY2035 from a FY2016 base year.
2030
65% reduction in Scope 2
Takeda Pharmaceutical Company commits to reduce absolute scope 2 GHG emissions 65% by FY2030 from a FY2016 base year.
2040
Takeda Pharmaceutical Company commits to reduce absolute sco…
Takeda Pharmaceutical Company commits to reduce absolute scope 2 GHG emissions 65% by FY2030 from a FY2016 base year.
See all 8 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Takeda’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more